


















































Aniket Mishra,1 Raffaele Ferrari,2 Peter Heutink,3,4 John Hardy,2 Yolande Pijnenburg5 and 
Danielle Posthuma1,6 on behalf of the International FTD-Genomics Consortium 
 
 
1 Department of Complex Trait Genetics, VU University, Center for Neurogenomics and Cognitive 
Research, Amsterdam, 1081 HV, 
The Netherlands 
2 Department of Molecular Neuroscience, UCL, Russell Square House, 9-12 Russell Square House London, 
WC1B 5EH, UK 
3 Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tu¨ 
bingen, 72076, Tu¨ bingen, 
Germany 
4 German Center for Neurodegenerative Diseases (DZNE)-Tu¨ bingen, 72076, Tu¨ bingen, Germany 
5 Alzheimer Center and Department of Neurology, VU University Medical Center (VUMC), Neuroscience 
Campus Amsterdam, 
Amsterdam, 1081 HV, The Netherlands 
6 Department of Clinical Genetics, VU University Medical Center (VUMC), Neuroscience Campus 
Amsterdam, Amsterdam, 1081 










Correspondence to: Dr Aniket Mishra 
Department of Complex Trait Genetics, VU University, Center for Neurogenomics and 
Cognitive Research, Amsterdam, 1081 HV, The Netherlands 
E-mail: aniket.mishra@u-bordeaux.fr 











ABSTRACT   
 
Genome-wide association studies in frontotemporal dementia showed limited success in identifying 
associated loci. This is possibly due to small sample size, allelic heterogeneity, small effect sizes of single 
genetic variants, and the necessity to statistically correct for testing millions of genetic variants. To overcome 
these issues, we performed gene-based association studies on 3348 clinically identified frontotemporal 
dementia cases and 9390 controls (discovery, replication and joint-cohort analyses). We report association 
of APOE and TOMM40 with behavioural variant frontotemporal dementia, and ARHGAP35 and SERPINA1 
with progressive non-fluent aphasia. Further, we found the "2 and "4 alleles of APOE harbouring protective 
and risk increasing effects, respectively, in clinical subtypes of frontotemporal dementia against 
neurologically normal controls. The APOE-locus association with behavioural variant frontotemporal 
dementia indicates its potential risk-increasing role across different neurodegenerative diseases, whereas the 
novel genetic associations of ARHGAP35 and SERPINA1 with progressive non-fluent aphasia point towards 










Abbreviations: bvFTD = behavioural variant of frontotemporal dementia; GWAS = genome-wide 
association study; FTD = frontotemporal dementia; MND = motor neuron disease; LD = linkage 
disequilibrium; MAGMA = Multi-marker Analysis of GenoMic Annotation; PNFA = progressive non-fluent 
























Frontotemporal dementia (FTD) is one of the leading causes of dementia in patients younger than 65 years 
of age (Rabinovici and Miller, 2010; Seelaar et al., 2011). It is characterized by degeneration of the frontal 
and anterior temporal lobes leading to a decline in behaviour and language. FTD is a heterogeneous 
condition clinically, pathologically and genetically (Cairns et al., 2007; Seelaar et al., 2011). Clinically, it is 
broadly categorized into the behavioural variant (bvFTD) and the language variant or primary progressive 
aphasia (PPA), which is further categorized into semantic dementia and progressive non-fluent aphasia 
(PNFA). There is frequent overlap between the presence of FTD and a number of motor diseases such as 
parkinsonian disorders, corticobasal syndrome, progressive supranuclear palsy and motor neuron disease 
(FTD-MND) (Rohrer et al., 2009). The underlying pathological spectrum of FTD, termed frontal temporal 
lobar degeneration (FTLD), is based on neuronal lesions and protein inclusions such as with tau or TAR-
DNA binding protein (TDP)-43 pathology. Besides the Mendelian genes MAPT, GRN and C9orf72 that are 
causal in up to 30–50% of familial FTLD cases, rare variability in few other genes has been implicated in 
55% of cases (Rohrer et al., 2009; Ferrari et al., 2013; Woollacott and Rohrer, 2016). To date, few large 
genome wide association studies (GWAS) have been performed for FTD (Van Deerlin et al., 2010; Ferrari et 
al., 2014, 2015) reporting an association with TMEM106B for FTLD with TDP-43 pathology (Van Deerlin 
et al., 2010), and with the locus comprising RAB38 and CTSC as well as the HLA-DRA/HLA-DRB5 locus 
for bvFTD and FTD, respectively (Ferrari et al., 2014). 
In a typical GWAS, an association test on a single variant [single nucleotide polymorphisms (SNPs) or 
Indels] is performed to map genes associated with a phenotype; however, many independent risk alleles for 
a given phenotype can be localized within a gene (Yang et al., 2012; Tada et al., 2014; Zhang et al., 2014). 
Hence a classical GWAS approach will be less powered to detect genes containing many independent risk 
alleles (Hagg et al., 2015). A joint-variant gene-based test that combines independent association signals 
within a gene while accounting for the linkage disequilibrium (LD) between variants can overcome this 
limitation. A number of approaches have been reported to perform joint-SNP gene-based analysis: the 
permutation test—where empirical evidence of association of the combined test statistics is calculated by 
shuffling the samples while keeping markers intact—is currently considered the golden standard (Liu et al., 
2010). However, the requirement of genotype data and computational burden limits its use. Recently, our 
group developed a new approach called Multi-marker Analysis of GenoMic Annotation (MAGMA) that 
uses a multiple regression model to perform joint-SNP gene-based analysis using GWAS summary data (de 
Leeuw et al., 2015). 
In this study, we performed a hypothesis free gene-wide association study on FTD subtypes (bvFTD, 
semantic dementia, PNFA and FTD-MND) using GWAS summary files obtained from the International 
FTD-Genomics consortium (IFGC) (Ferrari et al., 2014). We used the MAGMA software to perform the 
gene-based analysis. We report results of discovery, replication and combined cohort analyses for each FTD 
subtype; we also assessed individual risk variants for associated genes, which can be used for replication in 




The dataset used in the FTD-GWAS was described previously (Ferrari et al., 2014). Briefly, 44 international 
groups contributed clinical FTD samples. Patients were diagnosed according to the Neary criteria or the 
revised criteria for bvFTD and language variants of FTD (Neary et al., 1998; Gorno- Tempini et al., 2011; 
Rascovsky et al., 2011). Approximately 3% of cases were pathologically confirmed. To each individual 
case two ancestry and age-matched neurologically normal controls were assigned. For the current study we 
used the GWAS summary datasets of the discovery and replication cohorts of each FTD subtype, bvFTD 
(discovery: 1377 cases and 2754 controls; replication: 690 cases and 5092 controls), PNFA 
(discovery: 269 cases and 538 controls; replication: 221 cases and 5092 controls), semantic dementia 
(discovery: 308 cases and 616 controls; replication: 189 cases and 5092 controls) and FTD-MND 
(discovery: 200 cases and 400 controls; replication: 94 cases and 5092 controls). Overall bvFTD, PNFA, 





We performed the joint-SNP gene-based analysis using MAGMA (de Leeuw et al., 2015). The MAGMA 
approach is based on a multiple linear principal components regression model. By projecting the 
multivariate LD matrix of SNPs in a gene it first extracts principal components that explain genetic 
variation. These principal components are further used as predictors of a phenotype under a linear regression 
framework. MAGMA then uses Fisher’s test to compute P-values to test association between a gene and the 
phenotype. 
We used 19 418 hg19 annotated protein-coding genes to perform the analysis. As all the samples involved 
were of European descent, we used the 1000 Genomes phase 1 European reference population to estimate 
LD between variants (1000 Genomes Project Consortium et al., 2012). We only considered SNPs in the 5’- 
and 3’-untranslated region (UTR) and the open reading frame for the joint-SNP gene-based tests. This 
strategy resulted in loss of cis- regulatory variants, but was more stringent and open reading framespecific. 
The schematic representation of the strategy for multi-stage gene-wide association analysis for FTD and 
subtypes is described in Supplementary Fig. 1. We performed separate gene-based tests using discovery and 
replication datasets for each FTD subtype reported previously by the IFGC (Ferrari et al., 2014). We 
performed gene-based tests using only those variants that were either genotyped or imputed with imputation 
score 40.50. Moreover, we only considered common variants with minor allele frequency 40.01. For 
individual 
FTD subtypes, 4 303 460 and 55 375 variants were available for the gene-based analysis in the discovery 
and replication cohorts, respectively. Further, 16 313 and 10 349 genes that contained at least one variant 
within the 5’-, 3’-UTR and open reading frame, were tested for association with a given FTD subtype in the 
discovery and replication cohorts, respectively. To identify additional genes associated with individual 
FTD subtypes, we meta-analysed the gene-based P-values obtained in the discovery and replication cohorts 
using the Stouffer’s combination approach for the sample size weighted combination of P-values. For each 
FTD subtype we tested association of total 16 920 genes either in the discovery or replication cohorts.  
 
To correct for multiple association tests performed for 16 920 genes with one of the four subtypes of 
FTD, we applied the conservative Bonferroni correction method establishing a gene-wide significance 
threshold at 7.388   10 7 [= 0.05 / (4   16 920)]. To identify genes associated with any FTD subtype, we 
combined the gene-based test statistics for either subtype (bvFTD, semantic dementia, PNFA 
and FTD-MND) using the sample size weighted Stouffer’s combination method. 
 
Functional characterization of associated genes 
We downloaded the gene expression profiles of the associated genes across 13 human brain tissues (in 
alphabetical order: amygdala, anterior cingulate cortex, caudate, cerebral hemisphere, cerebellum, cortex, 
frontal cortex, hippocampus, nucleus accumbens, putamen, spinal cord, substantia nigra) using the GTEx 
portal (Mele et al., 2015) (GTEx Analysis V6 dbGaP Accession phs000424.v6.p1). We also investigated 
the functional annotations of variants that are in LD (r240.8 in the 1000 Genomes phase 1 European panel) 
with SNPs used in deriving gene-based P-values of the associated genes using software HaploReg (Ward 
and Kellis, 2012) (version 4.1) and RegulomeDB (Boyle et al., 2012) (version 1.1). 
 
Results 
Associations with frontotemporal dementia and its subtypes 
Behavioural variant frontotemporal dementia 
In the discovery cohort, two genes passed the gene-wide significant P-value threshold 7.39   10 7: 
TOMM40 (P = 5.79   10 8) and APOE (P = 1.37   10 7). In the replication cohort the P-values were 
6.40   10 5 for TOMM40 and 1.69   10 3 for APOE suggesting consistency of associations across 
independent bvFTD samples. No other genes passed the significance threshold for the bvFTD subtype 
(Supplementary Fig. 2A). 
Interestingly, in the discovery cohort the SNPs rs7412 and rs429358, which determine three epsilon (") 
alleles "2, "3 and "4 of the APOE gene, were among the SNPs driving its association with bvFTD, with P-
values 0.023 (rs7412) and 5.04   10 6 (rs429358). In the replication cohort rs429358 was not genotyped, 
whereas information on rs769449, an intronic variant in high LD (r2 = 0.82, 1000 Genomes phase 1 
European population) with rs429358, was available; here the P-values were 0.222 for 
rs7412 and 1.95   10 4 for rs769449. 
To check whether the association of TOMM40 with bvFTD was independent of the epsilon variants, we 
reperformed the gene-based test on TOMM40 gene using only those variants in negligible LD (r250.2) with 
rs7412 and rs429358 in 1000 Genomes phase 1 European panel. This analysis showed moderate association 
of TOMM40 with bvFTD (P = 7.51   10 6; Table 1) suggesting that the TOMM40 gene harbours signals 
for the risk of bvFTD that are independent of the epsilon alleles of APOE gene. 
The summary statistics of variants used for deriving gene- based P-values for TOMM40 and APOE are 
given in Supplementary Tables 1A and B, respectively, and the regional plots are shown in Fig. 1A and B. 
The regional plots show many variants in TOMM40 with P-values50.05 that are in negligible LD (r250.2) 
with rs769449, a proxy of epsilon variant rs429358. Furthermore we did not find significant gene-based 
association of RAB38 gene, which was identified as associated with bvFTD using the SNP-based GWAS. 
The association P-value of RAB38 gene in our joint-SNP gene-based analysis might be diluted due to 
inclusion of many non-risk variants, refer to Supplementary Fig. 3A and B for regional association plots at 
the RAB38 gene showing many nonrisk variants within the gene’s transcription site. 
 
Progressive non-fluent aphasia 
The joint-cohort (discovery and replication) analysis revealed association for ARHGAP35 (P = 2.95   
10 7) and SERPINA1 (P = 3.02   10 7) with PNFA (Table 1 and Supplementary Table 2). The regional 
plots for ARHGAP35 and SERPINA1 (Fig. 2A and B, respectively) show a robust LD block only for 
ARHGAP35 for which all variants show association P-values50.05 with PNFA (also refer to Supplementary 




No gene exceeded the gene-wide significance threshold 7.39   10 7, possibly because of the smaller 
sample size for this subtype, thus reduced power. The top gene identified in the combined analysis was 
WDR66 (P = 9.50   10 6, Table 1). 
 
 
Frontotemporal dementia-motor neuron disease 
No gene reached gene-wide significant association in the FTD-MND subtype. However, the top genes for 
FTDMND were C9orf72 and IFNK with gene-based association P-value in joint-cohort analysis 1.23   
10 6 and 1.77   10 6, respectively. Neither gene showed associations with any other subtypes of FTD 
(Table 1). 
 
Frontotemporal dementia meta-analysis 
The meta-analysis across all subtypes (bvFTD, semantic dementia, PNFA and FTD-MND) identified 
association of TOMM40 and APOE. It is worth noting that the bvFTD samples make nearly two-thirds of 
the total sample; hence, P-values for association with bvFTD dominated the metaanalysis of FTD subtypes. 
 
Risk of APOE alleles on frontotemporal dementia subtypes 
Based on the gene-based association results with TOMM40 and APOE we extended our analysis to the 
epsilon alleles and genotypes. We compared each FTD case cohort (discovery, replication and combined) 
against a total of 9390 ancestry-matched controls using Fisher’s exact test. For replication cohorts, we used 
rs769449 as a proxy for rs429358. The distribution of epsilon alleles and genotypes in our cohort is given in 
Supplementary Tables 3 and 4, respectively. We established the significance threshold for allele 
associations as 4.17   10 3 (0.05/12) correcting for three epsilon alleles and four FTD subtypes. We 
identified that the "2 allele significantly reduces the risk of bvFTD [odds ratio (OR) = 0.772, P = 3.88   
10 4] and semantic dementia (OR = 0.651, P = 3.64   10 3). We observed marginal association (P50.05) 
of "2 allele with PNFA (OR = 0.706, P = 0.019) and moderate with FTD-MND (OR = 0.571, P = 6.01   
10 3). The "4 allele significantly increased risk of bvFTD (OR = 1.278, P = 8.14   10 6) and semantic 
dementia (OR = 1.438, P = 2.93   10 4). The association for the disease increasing effect of "4 
allele was marginal (P50.05) for PNFA (OR = 1.298, P = 0.011), and the result was inconclusive for 
FTDMND (OR = 1.188, P = 0.202) possibly due to underpowered sample size. 
 
We also quantified the risk of homozygous "4/"4 genotype on FTD subtypes. We used 1.25   10 2 as a 
significance threshold for association testing of four subtypes  with homozygous "4/"4 genotype. The 
homozygous "4/"4 genotype showed significant association with increased risk for bvFTD (OR = 1.627, P = 
0.012), PNFA (OR = 2.367, P = 8.52   10 3) and semantic dementia (OR = 2.333, P = 9.08   10 3) with 
notable P- and OR-values for PNFA and semantic dementia compared to the effect size of a single copy of 
"4 allele for respective FTD subtypes. We did not perform association between homozygous "2/"2 
genotypes with FTD subtypes due to its low frequency in our cohort. 
 
Functional characterization of associated genes 
We extracted the gene expression profiles of APOE, TOMM40, ARHGAP35 and SERPINA1 across 
different human brain tissues from the GTeX database (Mele et al., 2015) (see Supplementary Fig. 4A–D for 
respective genes). The APOE, TOMM40 and ARHGAP35 genes are strongly expressed in different brain 
tissues. Notably the anterior cingulate cortex (Brodmann area 24) and the frontal cortex (Brodmann area 9) 
are the top tissues for ARHGAP35 gene expression. The anterior cingulate cortex is one of the early affected 
regions in FTD patients (Seeley et al., 2006, 2008); this area is reported to be involved in language control 
and resolving non-verbal conflict (Abutalebi et al., 2012). The SERPINA1 gene did not show strong 
expression in the brain tissues. 
We used the HaploReg (version 4.1) software (Ward and Kellis, 2012) to investigate functionally annotated 
variants linked with variants used in deriving gene-based P-values of TOMM40 (those in negligible LD 
r250.2 with epsilon variants), ARHGAP35, and SERPINA1, respectively. We found that all SNPs used in 
deriving gene-based P-values of TOMM40, ARHGAP35 and SERPINA1 are in strong LD 
(r240.8, in 1000 Genomes phase 1 European panel) with at least one variant residing in the regulatory 
regions such as chromatin marks or DNase hypersensitive sites, suggesting a possible regulatory role (see 
Supplementary Tables 5A–C for HaploReg results for variants in TOMM40, ARHGAP35 and SERPINA1, 
respectively). Overall we identified 21, 56 and 93 regulatory variants in LD with SNPs driving gene-based 
P-values of TOMM40, ARHGAP35 and SERPINA1 genes, respectively. We further ranked these regulatory 
variants based on their functional relevance using the RegulomeDB (version 1.1) software (Boyle et al., 
2012) (see Supplementary Tables 6A–C for detailed RegulomeDB results of these variants mapped to 
TOMM40, ARHGAP35 and SERPINA1 genes, respectively). 
 
Discussion 
Here we report novel genetic insight into FTD and its clinical subtypes using a joint-SNP gene-based 
approach. We identified association of the TOMM40 and APOE genes with bvFTD, and the ARHGAP35 
and SERPINA1 genes with PNFA. 
Our study suggested TOMM40 as the top gene in bvFTD. The TOMM40 gene encodes a channel forming 
subunit of the translocase of the mitochondrial outer membrane (TOM complex), which facilitates 
translocation of unfolded proteins from the cytosol into the mitochondrial intermembrane space for use in 
oxidative phosphorylation (Mager et al., 2011). Recently, Bannwarth et al. (2014) reported mitochondrial 
origin in pathogenesis of FTDALS diseases through association of variants in CHCHD10. There is growing 
evidence suggesting a role of mitochondria in neurodegenerative disorders, also including Parkinson’s 
disease (Parker et al., 1989; Schapira et al., 1990), Huntington’s disease (Moran et al., 2012) and 
Alzheimer’s disease (Petrozzi et al., 2007; Hroudova et al., 2014). Our conditional analysis suggests the 
TOMM40 association with bvFTD being independent from the epsilon alleles; however, interdependence 
with the epsilon alleles cannot be fully excluded at this stage. Future, more sophisticated, sequencing studies 
might further confirm the independence we highlight here. 
The association of the APOE gene with bvFTD was primarily driven by SNPs rs7412 and rs429358 (or 
variants in strong LD such as rs769449) suggesting that, if on one hand the TOMM40 association is 
independent from the epsilon alleles, on the other the APOE association (which is, however, lower 
comparatively to that of TOMM40) is dependent on the epsilon alleles lending support for the inference to 
be made that two different haplotypes at this locus might confer risk differently. The SNPs rs7412 and 
rs429358 determine the APOE epsilon alleles "2, "3 and "4. We quantified the risk of epsilon alleles across 
clinical subtypes of FTD diagnosed using the Neary’s criteria against neurologically normal controls, and 
saw that the "2 and "4 alleles showed protective and increased disease risk effects, respectively, for FTD 
subtypes (strong associations for bvFTD and semantic dementia, and marginal associations for PNFA and 
FTD-MND). Interestingly, individuals carrying homozygous copies of the "4 allele revealed higher risk for 
PNFA and semantic dementia (OR42.3) suggesting dose-dependent effect for each copy of a gene. The 
pattern of association of epsilon alleles with FTD subtypes might reflect the potential overlap between 
patients diagnosed with clinical FTD and Alzheimer’s disease (van der Zee et al., 2008; Bang et al., 2015) or 
a genuine association with FTD and its subtypes given the increasing number of studies arguing in favour of 
the latter hypothesis (Engelborghs et al., 2006; Agosta et al., 2009; Seripa et al., 2011; Rubino et al., 2013; 
Ferrari et al.,2015). 
In the CNS, APOE is synthesized in response to neuronal injury or stress to initiate the neuronal repair 
mechanisms. The "4 carriers are hypothesized to have reduced neuronal repair capacity compared to the 
other alleles (Rubino et al., 2013). The protein products of APOE were also reported to modulate 
neuroinflammation (Tai et al., 2015). The hypothesis of enhanced inflammatory response in FTD patients 
is supported by both neuroimaging and genetic studies (Cagnin et al., 2004; Rainero et al., 2009). Tau 
pathology is found in up to  50% of FTLD cases (Halliday et al., 2012); interestingly the knock-in study in 
mice showed association between epsilon alleles and the concentration of hyper-phosphorylated tau in 
neurons: "4 knock in mice showed higher concentration of hyper-phosphorylated tau than "3 knock in mice 
(Inbar et al., 2010). 
It is worth noting that in this scenario the APOE locus and the epsilon allelic variability might impact 
processes such as modulation of neuronal repair mechanisms, neuroinflammation, broad lipid metabolism, 
synaptic plasticity, neuronal toxicity and tau phosphorylation (Verghese et al., 2011). It is likely that 
variability in the genes or isoforms turnover or larger haplotype blocks at this locus, coupled 
with ageing, might influence negative outcomes in brain and thus support our findings from a biological and 
functional perspective. More work should be directed towards testing these possibilities in the future. 
Our study is the first to report association of the ARHGAP35 and SERPINA1 genes with PNFA. The 
ARHGAP35 gene encodes the glucocorticoid receptor DNA-binding factor 1, which is a repressor of 
glucocorticoid receptor (hGR) transcription. At the cellular level, the glucocorticoid receptor mediates the 
maintenance of basal and stress-related homeostasis. The second gene we found associated with PNFA was 
SERPINA1, which was previously reported to be associated with cortisol level (Bolton et al., 2014) (top 
variants: rs11621961, rs12589136, rs2749527) and serum lipid profile (Inouye et al., 2012) (top variant: 
rs1303). The non-synonymous variant rs1303 (Glu400Asp) in SERPINA1, which is also in moderate 
LD with morning plasma cortisol level associated variant rs12589136 (Bolton et al., 2014), showed PNFA 
association P-values50.05 in both discovery and replication cohorts (Supplementary Table 2B). The top 
SERPINA1 variant in the PNFA discovery cohort rs11628917 (this variant in moderate LD with rs1303) is 
an established blood eQTL (Westra et al., 2013), with the C allele increasing SERPINA1 expression in 
blood (Inouye et al., 2012; Westra et al., 2013). We observed that the C allele at rs11628917 increased the 
risk of PNFA in both discovery (OR = 2.893, P = 2.58   10 6) and replication (OR = 1.385, P = 0.077) 
cohorts. The SERPINA1 gene encodes protease inhibitor  1-antitrypsin enzyme, which inhibits 
cleavage of the reactive centre loop of the corticosteroid binding globulin (CBG) by ceasing neutrophil 
elastase activity (Lewis and Elder, 2014). The reactive centre loop cleavage by neutrophil elastase reduces 
the CBG binding affinity to cortisol. During stress CBG activity is positively correlated with the 
glucocorticoid access to the brain (Moisan et al., 2014). Increased glucocorticoid level in brain can activate 
glucocorticoid signalling through binding to the low affinity glucocorticoid receptors and result in reduced 
neurogenesis and impaired neuroplasticity (Anacker et al., 2011). This hypothesis suggesting the role 
of enhanced glucocorticoid signalling leading to neurodegeneration in PNFA patients is based on our current 
preliminary report on association of ARHGAP35 and SERPINA1 with PNFA; this finding will need to be 
further explored and replicated in an independent cohort. 
In conclusion, we report genetic associations for FTD and its subtypes—notably of the TOMM40 and APOE 
genes with bvFTD and the ARHGAP35 and SERPINA1 genes with PNFA—using the joint-SNP gene-based 
approach. 
This approach improves power of the association test by combining signals across variants in a functional 
unit such as a gene. Replication and functional characterization of these findings will further establish their 
role in pathology of FTD and help towards a better management of the disease. 
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